GlassScriptPhysician profile
Paul Jarczyk
NPI 1952322125
$724.86
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $13.04 · 2021: $288 · 2022: $50.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $212.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $174.49 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2019 | |
| Avanir Pharmaceuticals, INC. | $120.51 | 2019 | |
| Alexion Pharmaceuticals, INC. | $50.00 | 2021 | |
| Allergan, INC. | $29.20 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $13.04 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jarczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.